구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Humira (adalimumab) | Anti-TNF |
Overview Company | AbbVie | Abu Dhabi Stem Cells Center |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | Dementia |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | Rheumatoid Arthritis |
Overview Phase | APPROVED | PHASE_3 |
Overview Status | APPROVED | ACTIVE |
Overview Content status | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | novel object recognition test | — |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. | — |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). | Targeting viral protein‑host signaling |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). | biomarkers, microbiome profiling, and artificial intelligence in enabling adaptive and personalized asthma ma |
PK/PD Half-life | ~14–19 days (SC) | 248.54 days |
PK/PD Species | Rat, xenografts, which corroborat, CRP reduction, clinical remission scores | Mouse |
PK/PD Animal (cat.) | Rat | Mouse |
PK/PD Experiment | pd | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Rat, xenografts, which corroborat | Mouse |
Toxicology Animal (cat.) | NHP | Mouse |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.. The WHO International Nonproprietary Names (INN) system for monoclonal antibodies underwent its most fundamental revision in 2021-2022, retiring the universal -mab suffix and replacing it with four structure-based stems (-tug, -bart, -ment, -mig). Simultaneously, new … |
Toxicology CRS | N/A | grade 3 |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.. The WHO International Nonproprietary Names (INN) system for monoclonal antibodies underwent its most fundamental revision in 2021-2022, retiring the universal -mab suffix and replacing it with four structure-based stems (-tug, -bart, -ment, -mig). Simultaneously, new … |
Clinical Result source | ClinicalTrials.gov NCT02405780 | — |
Clinical Program phase | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02405780 | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Humira (adalimumab) | Anti-TNF |
Overview Company | AbbVie | Abu Dhabi Stem Cells Center |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | Dementia |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | Rheumatoid Arthritis |
Overview Phase | APPROVED | PHASE_3 |
Overview Status | APPROVED | ACTIVE |
Overview Content status | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | novel object recognition test | — |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. | — |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). | Targeting viral protein‑host signaling |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). | biomarkers, microbiome profiling, and artificial intelligence in enabling adaptive and personalized asthma ma |
PK/PD Half-life | ~14–19 days (SC) | 248.54 days |
PK/PD Species | Rat, xenografts, which corroborat, CRP reduction, clinical remission scores | Mouse |
PK/PD Animal (cat.) | Rat | Mouse |
PK/PD Experiment | pd | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Rat, xenografts, which corroborat | Mouse |
Toxicology Animal (cat.) | NHP | Mouse |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.. The WHO International Nonproprietary Names (INN) system for monoclonal antibodies underwent its most fundamental revision in 2021-2022, retiring the universal -mab suffix and replacing it with four structure-based stems (-tug, -bart, -ment, -mig). Simultaneously, new … |
Toxicology CRS | N/A | grade 3 |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.. The WHO International Nonproprietary Names (INN) system for monoclonal antibodies underwent its most fundamental revision in 2021-2022, retiring the universal -mab suffix and replacing it with four structure-based stems (-tug, -bart, -ment, -mig). Simultaneously, new … |
Clinical Result source | ClinicalTrials.gov NCT02405780 | — |
Clinical Program phase | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02405780 | — |
추천 비교
추천 비교